



**Universiteit
Leiden**
The Netherlands

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Sepriano, A.; Kerschbaumer, A.; Bergstra, S.A.; Smolen, J.S.; Heijde, D. van der; Caporali, R.; ... ; Landewe, R.B.M.

Citation

Sepriano, A., Kerschbaumer, A., Bergstra, S. A., Smolen, J. S., Heijde, D. van der, Caporali, R., ... Landewe, R. B. M. (2022). Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. *Annals Of The Rheumatic Diseases*, 82, 107-118.
doi:10.1136/ard-2022-223357

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/3503930>

Note: To cite this publication please use the final published version (if applicable).

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Alexandre Sepriano ^{1,2} Andreas Kerschbaumer ³ Sytske Anne Bergstra ²
 Josef S Smolen ^{3,4} Désirée van der Heijde ² Roberto Caporali^{5,6}
 Christopher J Edwards⁷ Patrick Verschueren ^{8,9} Savia de Souza ¹⁰
 Janet Pope ¹¹ Tsutomu Takeuchi ^{12,13} Kimme Hyrich ^{14,15}
 Kevin L Winthrop ¹⁶ Daniel Aletaha ³ Tanja Stamm ^{17,18}
 Jan W Schoones ¹⁹ Robert B M Landewé ^{20,21}

Handling editor David S Pisetsky

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/ard-2022-223357>).

For numbered affiliations see end of article.

Correspondence to

Dr Alexandre Sepriano, CHRC Campus Nova Medical School, Lisboa, 1169-056, Portugal; alexsepriano@gmail.com

Received 15 September 2022

Accepted 25 October 2022

Published Online First

14 November 2022

ABSTRACT

Objectives To perform a systematic literature review (SLR) concerning the safety of synthetic(s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) to inform the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis (RA).

Methods SLR of observational studies comparing safety outcomes of any DMARD with another intervention in RA. A comparator group was required for inclusion. For treatments yet without, or limited, registry data, randomised controlled trials (RCTs) were used.

Results Fifty-nine observational studies addressed the safety of DMARDs. Two studies (unclear risk of bias (RoB)) showed an increased risk of serious infections with bDMARDs compared with conventional synthetic (cs)DMARDs. Herpes zoster infections occurred more with JAKi than csDMARDs (adjusted HR (aHR): 3.66) and bDMARDs (aHR: 1.9–2.3) (four studies, two low RoB). The risk of malignancies was similar across bDMARDs (five studies) and with tofacitinib compared with bDMARDs (one study, low RoB). The risk of major adverse cardiovascular events (MACE) was similar with bDMARDs and tofacitinib (two studies, one low RoB). Thirty studies reported safety from RCTs, with one, designed to evaluate safety, showing that malignancies (HR (95% CI): 1.48 (1.04 to 2.09)) and MACE (HR (95% CI): 1.33 (0.91 to 1.94)) occurred numerically more frequently with tofacitinib (5 mg and 10 mg doses combined) than with TNFi in patients with cardiovascular risk factors. In this study, the risk of venous thromboembolism (VTE) was higher with tofacitinib 10 mg than with TNFi.

Conclusion The safety profile of bDMARDs was further demonstrated. Whether the difference in incidence of malignancies, MACE and VTE between tofacitinib and TNFi applies to other JAKi needs further evaluation.

INTRODUCTION

The main goals of the management of patients with rheumatoid arthritis (RA) include the relief of signs and symptoms, prevention of irreversible damage, improvement and normalisation of function, quality of life and social participation.^{1–3} Achieving these goals has become increasingly easier, thanks

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Since the 2019 EULAR recommendations for the management of rheumatoid arthritis (RA), new evidence has emerged on the safety of synthetic and biological disease-modifying antirheumatic drugs (bDMARDs) in RA.

WHAT THIS STUDY ADDS

⇒ The risk of malignancies and major adverse cardiovascular events (MACEs) is similar, or even decreased, with bDMARDs compared with conventional synthetic (cs)DMARDs.
 ⇒ Malignancies and MACE occurred more with tofacitinib than with TNFi in patients who had certain cardiovascular risk factors, especially in patients older than 65 years of age.
 ⇒ Herpes zoster is more common with JAKi than with csDMARDs or bDMARDs.
 ⇒ Lower intestinal perforations are rare but occur more often with tocilizumab than with other bDMARDs.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ This review informed the 2022 EULAR recommendations for the management of RA, highlighting new evidence on safety of synthetic and bDMARDs.

to, among others, a growing number of treatment options at the disposal of clinicians taking care of patients with RA.

Interventions currently approved in RA include conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).⁴ These ‘umbrella-terms’ include drugs with diverse modes of action. Drugs targeting TNF (TNF inhibitors; TNFi) the IL-6-receptor (IL-6R inhibitors; IL-6Ri), T cell co-stimulation and B cells, are examples of bDMARDs. JAK inhibitors (JAKi) are, thus far, the only tsDMARDs approved



© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Sepriano A, Kerschbaumer A, Bergstra SA, et al. *Ann Rheum Dis* 2023;**82**:107–118.

to treat RA. Despite their diverse mechanisms, these drugs have shown a remarkable overlap in efficacy.⁵ Safety aspects can, however, differ and thus influence treatment decisions in clinical practice.⁶

Safety is a key component of the development programme of new drugs. However, randomised controlled trials (RCTs) are usually designed to evaluate efficacy. Their short follow-up and the inclusion of selected patients limit their ability to study safety thoroughly.⁷ These challenges, among others, led to the development of patient registries. After regulatory approval, a new drug will be used in patients in clinical practice who subsequently can be enrolled in registries or other observational cohorts and databases. In the absence of RCTs designed to evaluate safety, observational studies stemming from real-world data sources in which drugs are directly compared in unselected patients over a long time, have regularly been used to inform management recommendations over the years.¹ Occasionally, large, long-term RCTs with a primary safety endpoint are designed, mostly on regulatory request,^{2,3} providing information on specific safety aspects of certain drugs at the highest level of evidence.

In order to inform the task force responsible for the 2022 update of the EULAR RA management recommendations,⁸ we performed a systematic literature review (SLR) to update the evidence for the safety of csDMARDs, bDMARDs and tsDMARDs in patients with RA. This SLR is an extension of the SLR performed previously for the corresponding 2019 update.⁶ The results of this and two other SLRs, one focusing on efficacy,⁹ and another one on glucocorticoids,¹⁰ provided the task force with the current state of evidence.

METHODS

Literature search

The steering group of the EULAR task force for the 2022 update of the RA management recommendations outlined the scope of the literature search according to the Population, Intervention, Comparator, Outcomes format and defined the criteria for a study being eligible.¹¹ The search was performed in MEDLINE, Embase, Web of Science and The Cochrane CENTRAL Register of Controlled Trials (Central), without language restrictions, and comprised publications from 1 January 2019 to 14 January 2022, as an update of the previous SLR.⁶ Details on complete search strategies are provided in online supplemental text 1. The literature search addressed the safety of DMARDs. Observational studies, namely cohort studies/registries with >50 cases were the main study type. Participants were adults (≥18 years old) with a clinical diagnosis of RA. Studies including patients with other diagnoses were eligible only if results from patients with RA were presented separately. The intervention was any DMARD (csDMARD, bDMARD—including biosimilars—or tsDMARD), including all drugs (chloroquine, hydroxychloroquine, leflunomide, methotrexate, sulfasalazine, abatacept, anakinra, adalimumab, brodalumab, certolizumab pegol, etanercept, golimumab, guselkumab, infliximab, ixekizumab, mavrimumab, ocrelizumab, ofatumumab, olokizumab, otilimab, rituximab, sarilumab, sirukumab, tabalumab, tocilizumab, ustekinumab, apremilast, baricitinib, decernotinib, evobrutinib, fenebrutinib, filgotinib, fostamatinib, peficitinib, ruxolitinib, tofacitinib, upadacitinib), formulations and duration. Studies were only eligible if they included a comparator group (either another DMARD, combination therapy, or the general population). Studies on glucocorticoids were excluded, as they were dealt with in a separate SLR.¹⁰ The following safety outcomes were considered: infections (including serious infections, opportunistic infections

such as tuberculosis (TB) and herpes zoster (HZ)), malignancies, mortality, major adverse cardiovascular events (MACEs), venous thromboembolism (VTE) including pulmonary embolism/deep venous thrombosis, changes in lipid levels, elevations of creatine phosphokinase, impairments in renal function, elevations of liver enzymes, haematological abnormalities, gastrointestinal side effects, demyelinating disease, induction of autoimmune disease, teratogenicity, fertility and pregnancy outcomes. For the risk of infection by SARS-CoV-2, only studies published after 31 May 2021 (the limit date of an SLR informing EULAR recommendations focusing on the topic) were considered.^{12,13} RCTs with a primary safety outcome were included. In addition, RCTs and long-term extensions (LTEs), selected in the accompanying SLR addressing efficacy,⁹ were also included to assess the safety of drugs without, or with limited real-world data available.

Selection of studies, data extraction and assessment of risk of bias

Two reviewers (AS and AK) independently screened 10% of all titles and abstracts, and if necessary, the full-text for eligibility. An agreement of 96% between the two reviewers was achieved for the decision to include a study and therefore the remaining screening was done only by one reviewer (AS). Data from eligible studies were extracted regarding study and population characteristics, inclusion/exclusion criteria, follow-up time, interventions, outcome definition and outcome measures using a standardised data extraction form. The risk of bias (RoB) of each included study was assessed using the 'Hayden-tool' for observational studies and The Cochrane Collaboration's tool for RCTs.^{14,15} Decisions on study selection, extraction and RoB assessment were discussed with a third reviewer (RBML) whenever necessary.

RESULTS

From a total of 2961 references (after de-duplication), 226 were selected for a full-text review and 59 observational studies fulfilled the inclusion criteria.^{16–74} In addition, 2 RCTs with a primary safety outcome,^{2,3} and 28 RCTs/LTEs from the efficacy SLR,^{75–102} were included (flow chart in online supplemental figure S1). Studies were heterogeneous, precluding data pooling, and results are presented descriptively.

Overview of observational studies

Of 59 observational studies, 51 assessed only 1 outcome,^{16–66} and 8 addressed ≥2 outcomes (online supplemental table S1–137).^{67–74} Of 27 studies evaluating the risk of infections,^{27–47, 67, 69, 71–74} 23 included patients on bDMARDs,^{27–29, 31–33, 35–37, 39–47, 69, 71–74} 9 of which also patients on JAKi,^{27, 28, 30, 31, 42, 45, 69, 71, 72} 3 only patients on csDMARDs^{34, 38, 67} and 1 patient either on tofacitinib or on csDMARDs.³⁰ Nine studies evaluated the risk of malignancies with bDMARDs,^{48–53, 71, 73, 74} and one of these also with tofacitinib.⁷¹ Thirteen studies assessed the risk of MACE,^{17–24, 67–71} with 11 including patients on bDMARDs,^{17–21, 23, 24, 67, 69–71} 6 of which included patients on JAKi^{20, 21, 24, 67, 69, 71} and 2 had patients only on csDMARDs.^{22, 68} Intestinal perforations^{25, 26} and neuroinflammatory events^{60, 61} were assessed in two studies, each in patients on bDMARDs. All-cause mortality with bDMARDs was assessed in seven studies.^{58, 59, 68–72} Seven studies addressed withdrawals due to adverse events with bDMARDs^{54–56, 63–66} and one with JAKi.⁵⁷ One study assessed any serious adverse events,⁶⁷ another any adverse event,¹⁶ both in patients with bDMARDs, and one evaluated pregnancy outcomes in patients on bDMARDs.⁶²

Overview of RCTs

Eleven studies evaluating bDMARDs,^{2 75 76 78 79 84 87 90 92 96 100} and 19 evaluating tsDMARDs were included (online supplemental tables S138–152).^{3 77 80–83 85 86 88 89 91 93–95 97–99 101 102} Most RCTs were not designed, and therefore, not powered, to evaluate safety outcomes. The incidence of major adverse events was low and, mostly comparable between active treatment, placebo or active comparator. The exception was the ORAL-Surveillance study,³ a non-inferiority trial in which patients ≥ 50 years old who failed methotrexate and had ≥ 1 cardiovascular risk factor were randomised to tofacitinib 5 mg two times per day, tofacitinib 10 mg two times per day, or TNFi (adalimumab or etanercept). The trial was designed to test whether the upper limit of the 95% CI around the risk ratio of MACE or malignancies for tofacitinib (5 mg and 10 mg two times per day combined) compared with TNFi, was below 1.8 (the non-inferiority question). In addition, the ENTRACTE trial, which had a similar design and non-inferiority margin, compared the risk of MACE (primary endpoint) between tocilizumab and etanercept.²

Infections

Observational studies

Of 27 studies addressing the risk of infections, 3 compared bDMARDs/JAKi to the general population,^{27 44 47} 8 compared bDMARDs/JAKi to csDMARDs,^{28 30–32 35 36 46 72} 3 compared the risk across csDMARDs,^{34 38 67} and 13 across bDMARDs/JAKi.^{29 33 35 37 39–43 45 69 71 74} (table 1 and online supplemental tables S2–S43).

The risk of serious infections was increased with bDMARDs compared with the general population in one study (adjusted HR (aHR): 4.1 (95% CI 3.6 to 4.7)),⁴⁴ and compared with csDMARDs in two studies, all at unclear RoB.^{35 36} The risk was similar across csDMARDs in two studies comparing different csDMARDs (one at low RoB).^{38 67} Seven studies reported a similar risk of serious infections across bDMARDs and two a lower risk with abatacept.^{29 32} Of note, the latter result was not seen in five other studies, including one at low RoB from the Danish registry (table 1).³⁹ Serious infections were not more common with tofacitinib than with bDMARDs in three studies, including one, at low RoB, from the CORRONA registry (aHR: 0.99 (95% CI 0.75 to 1.30)).^{42 45 71}

The risk of any opportunistic infection was not increased with TNFi plus methotrexate compared with triple csDMARD therapy,⁴⁶ and across bDMARDs (two studies at high and 1 at unclear RoB).^{33 74} In one study at low RoB from the German RABBIT registry, patients on monoclonal TNFi (aHR: 1.63 (95% CI 1.17 to 2.28)) and on rituximab (aHR: 1.57 (95% CI 1.03 to 2.40)), but not on other bDMARDs, were more likely to be infected by HZ than patients on csDMARDs.³¹ In the same cohort, the risk of HZ was also higher with JAKi (tofacitinib, baricitinib and upadacitinib) than with csDMARDs (aHR: 3.66 (95% CI 2.38 to 5.63)). Moreover, in three studies (one at low RoB) infections by HZ were more frequent with tofacitinib than with bDMARDs (table 1).^{40 45 69 71}

The risk of TB was not increased with bDMARDs compared with the general population in a study from Slovenia, where strict procedures for screening and treatment of latent TB were in place (one study at high RoB).⁴⁷ Another study at high RoB found a similar risk of TB with abatacept compared with other b/tsDMARDs.⁷⁴ The risk of pneumonia due to *Pneumocystis jirovecii* was increased with methotrexate combined with other csDMARDs, compared with methotrexate alone (aHR: 5.98 (95% CI 1.91 to 18.74)) (one study at high RoB).³⁴

Hospitalisation due to infection by SARS-CoV-2 was more likely with non-TNFi (analysed together) compared with csDMARDs and TNFi in one study,²⁷ and with rituximab compared with TNFi in another (both at high RoB).²⁸ However, in one study, at low RoB, the risk of hospitalisation due to infection by SARS-CoV-2 was similar with b/tsDMARDs and csDMARDs.⁷² Reactivation of the hepatitis B virus was more common with abatacept and rituximab (but not tocilizumab) than with TNFi in one study at unclear RoB.²⁹

Randomised controlled trials

In ORAL-Surveillance, the risk of serious infections was increased only with tofacitinib 10 mg two times per day compared with TNFi, while the risk of infections by HZ was increased both with tofacitinib 10 mg and 5 mg (figure 1). In two RCTs, infections by HZ were more common with filgotinib and upadacitinib than with placebo (table 2).^{86 89} Whereas, in five active-controlled RCTs the number of infections caused by HZ was higher with the JAKi upadacitinib (range: 0.8%–3%) than with an active comparator (0.3%–1.3%),^{80 94 101} but similar with the JAKi filgotinib (0.4%–1.0%) vs an active comparator (0.6%–1%).^{77 102}

Malignancies

Observational studies

The risk of malignancies was not increased with bDMARD use compared with the general population in two studies.^{50 53} In one of these, at low RoB, from the Swedish Rheumatology Quality Register,⁵³ there was a higher risk of lymphomas both in bDMARDs-naïve (aHR: 1.56 (95% CI 1.37 to 1.78)) and in bDMARD-treated (aHR: 1.65 (95% CI 1.31 to 2.08)) patients compared with the general population. In this study, the risk was lower with bDMARDs (TNFi and non-TNFi analysed together) than with methotrexate (aHR: 0.52 (95% CI 0.32 to 0.83)). One study at high RoB, found no difference in the risk of malignancies between TNFi and csDMARDs and another, at low RoB, found no difference between tofacitinib and bDMARDs.^{51 71} The risk of malignancies was, in general, similar across bDMARDs in five studies, with conflicting data for abatacept (table 3). Details on studies addressing malignancies are shown in online supplemental tables S44–S67.

Randomised controlled trials

Compared with TNFi, tofacitinib was associated with an increased risk of malignancies (HR: 1.48 (95% CI 1.04 to 2.09)) over 5.5 years in ORAL-Surveillance. Non-inferiority of tofacitinib could not be claimed for malignancies. In subgroup analyses, the incidence of malignancies was higher across all arms for patients aged ≥ 65 compared with patients aged < 65 (range: 1.1–1.9/100 PY vs 0.6–0.9/100 PY). In two LTEs up to 52 weeks, the incidence of malignancies was similar with JAKi (filgotinib and upadacitinib) and adalimumab in patients who, by design, did not had to have malignancy risk factors.^{77 83}

Major cardiovascular events

Observational studies

Thirteen studies evaluated the risk of MACE (table 4 and online supplemental tables S68–S100). In one study, at unclear RoB, patients on infliximab, etanercept and abatacept, but not on other bDMARDs or tofacitinib, had a lower risk of MACE compared with patients on csDMARDs.²⁰ In another study, the risk of MACE was lower if a bDMARD was combined with methotrexate than with a bDMARD alone.¹⁹ The risk of MACE was similar with tofacitinib and bDMARDs in one study, at low

Table 1 Serious infections, comparison between different bDMARDs/tsDMARDs (observational studies)

Study ID	Registry	Intervention	Control	aHR (i vs c)	Risk of bias
Serious infections					
Chen <i>et al</i> ⁴⁰ 2020	Claims dataset	ABA	TNFi	0.78 (0.64; 0.95)	High
Chen <i>et al</i> ⁴² 2021	Claims dataset	ETA	ABA	1.52 (0.45; 5.14)	High
		ADA		2.15 (0.63; 7.26)	
		GOL		1.24 (0.27; 5.58)	
		TCZ		1.90 (0.38; 9.61)	
		TOFA		NE	
Grøn <i>et al</i> ³⁹ 2019	DANBIO	ABA	RTX	0.95 (0.83; 1.10)	Low
		TCZ		0.98 (0.86; 1.12)	
		ABA	TCZ	0.98 (0.86; 1.10)	
Jeon <i>et al</i> ⁴¹ 2021	Claims dataset	TCZ	TNFi	1.00 (0.90; 1.11)	High
Kremer <i>et al</i> ⁷¹ 2021	CORRONA	TOFA	bDMARD	0.99 (0.75; 1.30)	Low
Montastruc <i>et al</i> ³⁷ 2019	Claims dataset	ABA	Other bDMARD	1.04 (0.89; 1.21)	High
Ozen <i>et al</i> ⁷³ 2019	FORWARD	ABA	other bDMARD	0.37 (0.18; 0.75)	Unclear
Pawar <i>et al</i> ⁴⁵ 2020	Claims dataset	TOFA	ABA	1.20 (0.97; 1.49)	High
			ADA	1.06 (0.87; 1.30)	
			CZP	1.02 (0.80; 1.29)	
			ETA	1.41 (1.15; 1.73)	
			GOL	1.23 (0.94; 1.62)	
			INF	0.81 (0.65; 1.00)	
			TCZ	1.17 (0.89; 1.53)	
Patel <i>et al</i> ⁴³ 2021	Claims dataset	TNFi	ABA	1.48 (1.26; 1.75)	High
		Non-TNFi		1.46 (1.28; 1.66)	
Simon <i>et al</i> ⁷⁴ 2019	Claims dataset	ABA	Other bDMARD	0.96 (0.84; 1.09)	High
Opportunistic infections					
Leon <i>et al</i> ³³ 2019	HC San Carlos	Non-TNFi	TNFi	1.11 (0.46; 2.69)	Unclear
Simon <i>et al</i> ⁷⁴ 2019	Claims dataset	ABA	other bDMARD	1.06 (0.96; 1.17)	High
Herpes Zoster					
Chen <i>et al</i> ⁴⁰ 2020	Claims dataset	ABA	TNFi	1.00 (0.73; 1.37)	High
Khosrow-Khavar <i>et al</i> ⁶⁹ 2022	Claims dataset	TOFA	TNFi	1.98 (1.78; 2.19)	High
Kremer <i>et al</i> ⁷¹ 2021	Corrona-RA	TOFA	bDMARD	2.32 (1.43–3.75)	Low
Pawar <i>et al</i> ⁴⁵ 2020	Claims dataset	TOFA	ABA	1.94 (1.53; 2.44)	High
			ADA	1.99 (1.63; 2.43)	
			CZP	2.24 (1.68; 2.99)	
			ETA	2.12 (1.73; 2.58)	
			GOL	1.84 (1.35; 2.50)	
			INF	1.94 (1.51; 2.50)	
			TCZ	2.14 (1.53; 2.99)	
Tuberculosis					
Simon <i>et al</i> ⁷⁴ 2019	Claims dataset	ABA	Other bDMARD	1.93 (0.45; 8.32)	High
Hospitalisation due to COVID-19					
Curtis <i>et al</i> ²⁷ 2021	Claims dataset	TOFA	non-TNFi	0.52 (0.25; 1.07)	High
		JAKi		0.60 (0.32; 1.10)	
		TNFi		0.32 (0.20; 0.53)	
Raiker <i>et al</i> ²⁸ 2021	Claims dataset	RTX	TNFi	1.78 (1.24; 2.54)	High
		IL6i		1.50 (1.00; 2.25)	
		JAKi		1.27 (0.95; 1.71)	
		ABA		0.84 (0.55; 1.29)	
Reactivation of hepatitis B					
Chen <i>et al</i> ²⁹ 2021	Taipei Veterans GH	TCZ	TNFi	NE	Unclear
		ABA		15.4 (3.1; 77.0)	
		RTX		35.6 (8.2; 155.8)	

Values in bold highlight statistically significant effect sizes. Additional details in online supplemental tables S2–S43.

ABA, abatacept; ADA, adalimumab; aHR, adjusted HR; bDMARD, biological disease-modifying antirheumatic drug; c, control; CORRONA, Consortium of Rheumatology Researchers of North America; CZP, certolizumab pegol; DANBIO, Danish nationwide quality registry; ETA, etanercept; FORWARD, National Databank for Rheumatic Diseases longitudinal prospective observational study; GH, general hospital; GOL, golimumab; HC, hospital clinico; i, intervention; IL6i, interleukin 6 inhibitor; INF, infliximab; JAKi, JAK inhibitor; NE, not possible to estimate (no cases of infections); RTX, rituximab; TCZ, tocilizumab; TNFi, TNF inhibitor; TOFA, tofacitinib; tsDMARD, targeted synthetic DMARD.




Figure 1 Incidence of major adverse events in patients with RA treated with tofacitinib compared with patients treated with a TNFi in the ORAL-Surveillance trial.³ If the HR is >1 there is an increased risk with tofacitinib compared with TNFi (statistically significant if the 95% CI does not include 1). Non-inferiority was not demonstrated for the two coprimary endpoints (malignancies and MACE), because the upper limit of the 95% CI for the comparison between tofacitinib (combined doses) and TNFi was above 1.8 (predefined non-inferiority margin). NNH formula: $(1/(\text{cases/PY in TOFA} - \text{cases/PY in TNFi}))/5$. NNH interpretation: number of patients who would need to be treated over 5 years with tofacitinib rather than with TNFi to result in one additional event. GIP, gastrointestinal perforations; MACE, major adverse cardiovascular event; NNH, number needed to harm; PY, patient-years; RA, rheumatoid arthritis; TNFi, TNF inhibitor; VTE, venous thromboembolism.

RoB (aHR: 0.61 (95% CI 0.34 to 1.06)).⁷¹ In another study, at high RoB, the risk of MACE was also similar with tofacitinib and TNFi both in a population representing ‘real-world’ patients (aHR: 1.01 (95% CI 0.83 to 1.23)), and in patients ≥ 50 years

old and ≥ 1 cardiovascular risk factor (aHR: 1.24 (95% CI 0.90 to 1.69)).⁶⁹

Four studies, at high RoB, evaluated the risk of VTE with csDMARDs and b/tsDMARDs.^{21–24} There was no difference in the risk of VTE between bDMARDs and csDMARDs in two studies.^{21, 23} In one of these, there was an increased risk only in patients who switched to a second b/tsDMARD compared with patients on csDMARDs.²¹ An increase in risk of VTE was found with methotrexate compared with hydroxychloroquine in another study at high RoB.²² Finally, in one study, the risk of VTE was similar with tofacitinib and TNFi (aHR: 1.13 (95% CI 0.77 to 1.65)).²⁴

Randomised controlled trials

Compared with TNFi, tofacitinib was associated with an increased risk of MACE (HR: 1.33 (95% CI 0.91 to 1.94)) over 5.5 years in ORAL-Surveillance (not statistically significant). Non-inferiority of tofacitinib could not be claimed for MACE. In subgroup analyses, the incidence of MACE was higher across all arms for patients aged ≥ 65 compared with patients aged < 65 (0.9–1.9/100 PY vs 0.7/100 PY). In ENTRACTE, the non-inferiority of tocilizumab compared with etanercept for the risk of MACE was demonstrated over a mean follow-up of 3.2 years (HR: 1.05 (95% CI 0.77 to 1.43)). In ORAL-Surveillance, the risk of VTE was increased only with tofacitinib 10 mg compared with TNFi. In two LTEs up to 52 weeks, the incidence of MACE was similar with JAKi (filgotinib and upadacitinib) and adalimumab in patients who, by design, did not have cardiovascular risk factors.^{77, 83}

Other adverse events

Observational studies

Studies evaluating other major outcomes are summarised in table 5 and reported in detail in online supplemental tables S101–S137). In a large study, at low RoB, lower intestinal perforations were uncommon but more frequent with tocilizumab (0.45/100 patient years (PY)) than with TNFi (0.18/100 PY) (aHR: 2.61 (95% CI 1.61; 4.24)). In another study, also

Study ID (trial)	Follow-up (weeks)	Treatment arm	N patients	HZ n (%)	Risk of bias
PBO-controlled trials					
Genovese <i>et al</i> ⁶⁶ 2019	24	FIL 200 + csDMARD	147	2 (1.4)	Low
		FIL 100 + csDMARD	153	2 (1.3)	
		PBO + csDMARD	148	0 (0.0)	
Kameda <i>et al</i> ⁶⁹ 2020	12	UPA 7.5+ csDMARD	49	1 (2.0)	Low
		UPA 15+ csDMARD	49	0 (0.0)	
		UPA 30+ csDMARD	50	3 (6.0)	
		PBO+ csDMARD	49	1 (2.0)	
Active-comparator trials					
Combe <i>et al</i> ⁷⁷ 2021	24	FIL 200+MTX	475	2 (0.4)	Low
		FIL 100+MTX	480	2 (0.4)	
		ADA+MTX	325	2 (0.6)	
		PBO+MTX	475	2 (0.4)	
Fleischmann <i>et al</i> ⁶⁰ 2019	26	UPA+MTX	650	5 (0.8)	Low
		ADA+MTX	327	1 (0.3)	
		PBO+MTX	652	3 (0.5)	
Rubbirt-Roth <i>et al</i> ⁶³ 2020	24	UPA 15+csDMARD	303	4 (1.3)	Low
		ABA+csDMARD	309	4 (1.3)	
Smolen <i>et al</i> ⁶⁴ 2019	14	UPA 15	217	3 (1.0)	Low
		UPA 30	215	6 (3.0)	
		MTX	216	1 (<1)	
van Vollenhoven <i>et al</i> ⁶⁰ 2020	24	UPA 15	317	7 (2.2)	Low
		UPA 30	314	7 (2.2)	
		MTX	314	1 (0.3)	
Westhovens <i>et al</i> ¹⁰² 2021	52	FIL 200+MTX	416	6 (1.0)	Low
		FIL 100+MTX	207	3 (1.0)	
		FIL 200	210	4 (2.0)	
		MTX	416	4 (1.0)	

ABA, abatacept; ADA, adalimumab; csDMARD, conventional synthetic disease-modifying antirheumatic drug; FIL, filgotinib; HZ, herpes zoster; MTX, methotrexate; PBO, placebo; tsDMARD, targeted synthetic DMARD; UPA, upadacitinib.

ABA, abatacept; ADA, adalimumab; csDMARD, conventional synthetic disease-modifying antirheumatic drug; FIL, filgotinib; HZ, herpes zoster; MTX, methotrexate; PBO, placebo; tsDMARD, targeted synthetic DMARD; UPA, upadacitinib.

Table 3 Malignancies, comparison between different bDMARDs/tsDMARDs (observational studies)

Study ID	Registry	Intervention	Control	aHR (i vs C)	Risk of bias
All types of cancer					
De Gernay <i>et al</i> ⁴⁸ 2020	Pharmacov. database	ABA	Other bDMARD	0.98 (0.91; 1.05)	High
Kim <i>et al</i> ⁴⁹ 2019	Claims dataset	TCZ	TNFi	0.98 (0.80; 1.19)	High
Montastruc <i>et al</i> ⁵² 2019	Claims dataset	ABA	Other bDMARD	1.17 (1.06; 1.30)	High
Ozen <i>et al</i> ⁷³ 2019	FORWARD	ABA	Other bDMARD	1.89 (0.93; 3.84)	Unclear
Kremer <i>et al</i> ⁷¹ 2021	CORRONA	TOFA	bDMARD	1.04 (0.68; 1.61)	Low
Simon <i>et al</i> ⁷⁴ 2019	Claims dataset	ABA	other bDMARD	1.09 (1.02; 1.16)	High
Non-melanoma skin cancer					
Kremer <i>et al</i> ⁷¹ 2021	CORRONA	TOFA	bDMARD	1.02 (0.69; 1.50)	Low
Montastruc <i>et al</i> ⁵² 2019	Claims dataset	ABA	Other bDMARD	1.45 (1.03; 1.39)	High
Ozen <i>et al</i> ⁷³ 2019	FORWARD	ABA	Other bDMARD	1.10 (0.57; 2.11)	Unclear
Melanoma					
De Gernay <i>et al</i> ⁴⁸ 2020	Pharmacov. database	ABA	Other bDMARD	1.56 (1.17; 2.08)	High
Kim <i>et al</i> ⁴⁹ 2019	Claims dataset	TCZ	TNFi	0.71 (0.36; 1.40)	High
Montastruc <i>et al</i> ⁵² 2019	Claims dataset	ABA	Other bDMARD	0.86 (0.38; 1.59)	High
Lymphoma					
De Gernay <i>et al</i> ⁴⁸ 2020	Pharmacov. database	ABA	Other bDMARD	0.76 (0.60; 0.97)	High
Hellgren <i>et al</i> ⁵³ 2021	SRQ	ADA	ETA	1.02 (0.52; 1.99)	Low
		INF		0.64 (0.27; 1.56)	
		CZP		<5 lymphomas	
		GOL		<5 lymphomas	
		ABA		1.61 (0.50; 5.22)	
		RTX		<5 lymphomas	
		TCZ		<5 lymphomas	
		ANA		<5 lymphomas	
Kim <i>et al</i> ⁴⁹ 2019	Claims dataset	TCZ	TNFi	1.31 (0.60; 2.88)	High
Simon <i>et al</i> ⁷⁴ 2019	Claims dataset	ABA	Other bDMARD	1.27 (0.94; 1.72)	High

Values in bold highlight statistically significant effect sizes. Additional details in online supplemental tables S44–S67).

ABA, abatacept; ADA, adalimumab; aHR, adjusted HR; ANA, anakinra; bDMARD, biological disease-modifying antirheumatic drug; c, control; CORRONA, Consortium of Rheumatology Researchers of North America; CZP, certolizumab pegol; ETA, etanercept; FORWARD, National Databank for Rheumatic Diseases longitudinal prospective observational study; GOL, golimumab; i, intervention; INF, infliximab; Pharmacov, pharmacovigilance; RTX, rituximab; SRQ, Swedish Rheumatology Quality Register; TCZ, tocilizumab; TNFi, TNF inhibitor; TOFA, tofacitinib; tsDMARD, targeted synthetic DMARD.

at low RoB, diverticular perforations (but not of other aetiologies) occurred more often with tocilizumab than with rituximab/abatacept (HR: 3.8 (95% CI 1.1 to 13.6)).²⁶ No studies evaluating the risk of intestinal perforations with other IL-6Ri could be included.

Neuroinflammatory events were not more common with TNFi compared with the general population⁶¹ and with csDMARDs.⁶⁰ The standardised mortality rate was similarly high for bDMARD users (1.8 (95% CI 1.7 to 2.0)) and non-users (1.5 (95% CI 1.4 to 1.5)) in one study at high RoB.⁵⁹ Another study, at low RoB, found a lower risk of death with bDMARDs than with csDMARDs,⁷² and two studies (one at low RoB) found no difference between tofacitinib and bDMARDs.^{69–71} Studies addressing the risk of withdrawals due to adverse events and any (serious) adverse events reported results in line with the known safety profile of b/tsDMARDs. (online supplemental tables S123–S137).

Randomised controlled trials

In ORAL-Surveillance, intestinal perforations were uncommon (tofacitinib 5 mg: 0.17/100 PY; tofacitinib 10 mg: 0.10/100 PY; TNFi: 0.08/100 PY) and did not occur significantly more frequently with tofacitinib 5 mg (HR: 2.20 (95% CI 0.68 to 7.15)) nor with tofacitinib 10 mg (HR: 1.29 (95% CI 0.35 to 4.80)) than with TNFi. No cases of intestinal perforation occurred in two other RCTs on IL-6Ri (sarilumab and olokizumab; online supplemental table S141),^{90–92} and in five out of

eight trials on JAKi (online supplemental table S148).^{77–86–89–93–94}

In ORAL-Surveillance, the risk of mortality was increased only with tofacitinib 10 mg compared with TNFi.

DISCUSSION

This SLR demonstrates that bDMARDs are relatively safe drugs in RA and also increases our knowledge of the safety of tsDMARDs, again showing they are relatively safe, although with some exceptions. The risk of malignancies and MACE is similar, or even decreased, with bDMARDs compared with csDMARDs. However, these adverse outcomes occurred more frequently with tofacitinib than with TNFi in patients who had certain cardiovascular risk factors. The risk of serious infections is increased with bDMARDs compared with csDMARDs and is similar across bDMARDs and tofacitinib. Of note, HZ is more common with JAKi than with csDMARDs or bDMARDs, with the possible exception of filgotinib. Lower intestinal perforations are rare but occur more often with tocilizumab than with other bDMARDs. Whether the overall safety profile differs across JAKi and across IL-6Ri remains unknown.

Randomisation is the main reason why RCTs are the ‘gold standard’ to test whether an outcome differs between two or more treatment groups. Randomisation ensures equal distribution of measured and unmeasured confounders between the different comparators. In most RCTs the primary outcome is an efficacy measure. Formal comparisons of safety outcomes

Table 4 MACE, comparison between different bDMARDs/tsDMARDs (observational studies)

Study ID	Registry	Intervention	Control	aHR (i vs c)	Risk of bias
MACE					
Hsieh <i>et al</i> ⁷⁰ 2020	Claims dataset	TCZ	RTX	0.41 (0.23; 0.72)	High
		ABA		0.25 (0.11; 0.55)	
Khosrow-Khavar <i>et al</i> ⁶⁹ 2022	Claims dataset	TOFA	TNFi	1.01 (0.83; 1.23)	High
Kremer <i>et al</i> ⁷¹ 2021	CORRONA	TOFA	bDMARD	0.61 (0.34; 1.06)	Low
Xie <i>et al</i> ¹⁸	Claims dataset	TNFi	TCZ	1.27 (1.02; 1.59)	High
		ADA		1.33 (0.99; 1.80)	
		ETA		1.10 (0.80; 1.51)	
		INF		1.61 (1.22; 2.12)	
		ABA		1.01 (0.79; 1.28)	
		RTX		1.16 (0.89; 1.53)	
Heart failure					
Hsieh <i>et al</i> ⁷⁰ 2020	Claims dataset	TCZ	RTX	0.48 (0.18; 1.31)	High
		ABA		0.20 (0.05; 0.83)	
Khosrow-Khavar <i>et al</i> ⁶⁹ 2022	Claims dataset	TOFA	TNFi	1.07 (0.79; 1.46)	High
Myocardial infarction					
Hsieh <i>et al</i> ⁷⁰ 2020	Claims dataset	TCZ	RTX	0.12 (0.02; 0.56)	High
		ABA		0.26 (0.06; 1.12)	
Khosrow-Khavar <i>et al</i> ⁶⁹ 2022	Claims dataset	TOFA	TNFi	1.04 (0.82; 1.33)	High
Xie <i>et al</i> ¹⁸ 2019	Claims dataset	TNFi	TCZ	1.20 (0.88; 1.62)	High
		ADA		1.24 (0.83; 1.87)	
		ETA		1.08 (0.71; 1.65)	
		INF		1.55 (1.05; 2.28)	
		ABA		1.01 (0.73; 1.40)	
		RTX		1.05 (0.72; 1.54)	
Stroke					
Hsieh <i>et al</i> ⁷⁰ 2020	Claims dataset	TCZ	RTX	0.54 (0.26; 1.12)	High
		ABA		0.18 (0.05; 0.64)	
Khosrow-Khavar <i>et al</i> ⁶⁹ 2022	Claims dataset	TOFA	TNFi	0.93 (0.66; 1.31)	High
Xie <i>et al</i> ¹⁸ 2019	Claims dataset	TNFi	TCZ	1.25 (0.90; 1.73)	High
		ADA		1.26 (0.80; 1.99)	
		ETA		1.09 (0.68; 1.75)	
		INF		1.49 (1.01; 2.21)	
		ABA		0.99 (0.70; 1.40)	
		RTX		1.10 (0.74; 1.63)	
Venous thromboembolism					
Desai <i>et al</i> ²⁴ 2021	Claims dataset	TOFA	TNFi	1.13 (0.77; 1.65)	High

Values in bold highlight statistically significant effect sizes. Additional details in online supplemental tables S68–S100.

i; intervention; ABA, abatacept; ADA, adalimumab; aHR, adjusted HR; bDMARD, biological disease-modifying antirheumatic drug; c, control; CORRONA, Consortium of Rheumatology Researchers of North America; ETA, etanercept; INF, infliximab; RTX, rituximab; TCZ, tocilizumab; TNFi, TNF inhibitor; TOFA, tofacitinib; tsDMARD, targeted synthetic DMARD.

are limited by lack of power. In addition, RCTs usually exclude patients at risk of adverse events and are too short to capture outcomes with long latency periods (eg, malignancies). This is why observational studies comparing the safety of drugs in unselected patients followed over long periods are the main study type of this SLR. Except for rare outcomes, for which studies are frequently underpowered, safety comparisons in real-world settings are most informative. In observational studies, however, treatment allocation is not at random. Therefore, the groups may have differences in their baseline risk of adverse outcomes (confounding by indication).⁷ The ideal study, combines the strengths of observational and experimental research. This SLR includes two of such studies, the ORAL-Surveillance and ENTRACTE trials.^{2,3}

The ORAL-Surveillance study shows that malignancies and MACE occur more often with tofacitinib than with TNFi in

patients with RA and cardiovascular risk factors (not statistically significant for MACE), especially in patients older than 65 years of age. In this population, one additional malignancy is expected to occur for each 55 patients who receive tofacitinib 5 mg two times per day instead of a TNFi over 5 years (NNH any time: 276). The 5-year number needed to harm is 113 for MACE (NNH any time: 567). These results led the European Medicines Agency (EMA) to caution against the use of tofacitinib in patients older than 65 years of age, current or past smokers or with other cardiovascular or malignancy risk factors (unless there is no alternative).^{103–106} EMA is conducting a safety review procedure to ascertain whether the risks identified for tofacitinib apply to all JAKi.¹⁰⁷ The Food and Drug Administration, on the other hand, considers the use of all JAKi only after failure of a TNFi and after a careful evaluation of the benefit–risk ratio.^{108–110}

Table 5 Intestinal perforations, neuroinflammatory events and mortality (observational studies)

Study ID	Registry	Intervention	Control	aHR (i vs C)	Risk of bias
Lower intestinal perforations					
Barbulescu <i>et al</i> ²⁵ 2020	ARTIS	ABA	TNFi	1.07 (0.55; 2.10)	Low
		RTX		0.89 (0.50; 1.58)	
		TCZ		2.20 (1.28; 3.79)	
Rempenault <i>et al</i> ²⁶ 2021	FSR*	TCZ	RTX/ABA	3.80 (1.10; 13.6)	Low
Neuroinflammatory events					
Kopp <i>et al</i> ⁶⁰ 2020	ARTIS & DANBIO	TNFi	csDMARDs	0.76 (0.44; 1.33)	Low
Taylor <i>et al</i> ⁶¹ 2021	BSRBR-RA	TNFi	General pop	SIR: 1.10 (0.71; 1.63)	Unclear
All-cause mortality					
Akhlaghi <i>et al</i> ⁵⁸ 2019	Mashhad	INF/ETA+MTX	MTX	0.97 (0.86; 1.09)	Unclear
Bower <i>et al</i> ⁷² 2021	ARTIS	TNFi	csDMARDs	0.57 (0.41; 0.79)	Low
		ABA		0.69 (0.39; 1.21)	
		TCZ		0.57 (0.27; 1.18)	
		RTX		1.04 (0.67; 1.63)	
		JAKi		0.80 (0.44; 1.45)	
		All b/tsDMARD		0.64 (0.48; 0.86)	
Faselis <i>et al</i> ⁶⁸ 2021	Claims dataset	HCQ	Other csDMARD	1.06 (0.84; 1.34)	High
Hsieh <i>et al</i> ⁷⁰ 2020	Claims dataset	TCZ	RTX	0.57 (0.34; 0.95)	High
		ABA		0.32 (0.15; 0.66)	
Khosrow-Khavar <i>et al</i> ⁶⁹ 2022	Claims dataset	TOFA	TNFi	1.20 (0.98; 1.46)	High
Kremer <i>et al</i> ⁷¹ 2021	CORRONA	TOFA	bDMARD	0.91 (0.59; 1.42)	Low
Lee <i>et al</i> ⁶⁹ 2022	Claims dataset	bDMARDs	General pop	SMR: 1.82 (1.69; 1.96)	High

Values in bold highlight statistically significant effect sizes. Additional details in online supplemental tables S101–S117.

ABA, abatacept; ADA, adalimumab; aHR, adjusted HR; ARTIS, anti-Rheumatic Treatment in Sweden Register; bDMARD, biological disease-modifying antirheumatic drug; BSRBR, British Society of Rheumatology Biologics Register; c, control; CORRONA, Consortium of Rheumatology Researchers of North America; csDMARD, conventional synthetic DMARD; DANBIO, Danish nationwide quality registry; ETA, etanercept; FSR, French Society of Rheumatology; HCQ, hydroxychloroquine; i, intervention; INF, infliximab; JAKi, JAK inhibitor; RTX, rituximab; TCZ, tocilizumab; TNFi, TNF inhibitor; TOFA, tofacitinib; tsDMARD, targeted synthetic DMARD.

A proper explanation for the results of ORAL-Surveillance is not immediately at hand. Patients with RA have a higher risk of MACE and malignancies than the general population, at least in part due to chronic inflammation.^{111–113} One study included in this SLR suggests, in line with others,^{114–115} that bDMARDs reduce the excess risk of MACE in RA more than csDMARDs.²⁰ Another study included in this SLR,⁵³ in contrast to a previous one,¹¹⁶ found a reduction of the excess risk of lymphoma with bDMARDs. It is reasonable to presume that these effects are mediated by the suppression of inflammation, however, that has not yet been proved. Besides, tofacitinib also suppresses inflammation, thus a similar effect would in principle be expected. Due to the lack of a csDMARD control group, the ORAL-Surveillance does not provide resolution. Thus, whether tofacitinib increases or, alternatively, is less efficacious than TNFi in suppressing the risk of MACE and cancer, remains unclear for now.

Of note, the results of ORAL-Surveillance differ from those of at least one observational study reporting no difference in the risk of MACE or malignancies between tofacitinib and bDMARDs.⁷¹ This study is however challenged by the possibility of residual confounding. With that being said, it should be noted that there was no age restriction for inclusion and patients did not have to have cardiovascular risk factors as in ORAL-Surveillance. These results together with the observation of a higher incidence of MACE and malignancies in ORAL-Surveillance in patients older than 65 years, and not in younger patients, suggests there could be a threshold effect. The higher the background risk, the more likely for the drug-attributable risk to become apparent. Obviously, this finding needs confirmation from a second independent RCT.

One important safety signal identified in the 2019 SLR was the risk of VTE with JAKi. In ORAL-Surveillance, there was a clear dose–response effect. Patients on tofacitinib 10 mg two times per day had a threefold increase in the risk of VTE compared with TNFi (especially PE), while the risk was lower and non-significant for the 5 mg two times per day dose. Of note, all patients randomised to tofacitinib 10 mg were considered in their original group, including those who switched to tofacitinib 5 mg in February 2019. These data led the regulators to warn that all JAKi should be used with caution in patients with risk factors for VTE.^{103–106} Available evidence is mostly limited to tofacitinib and more data, especially from studies in ‘real-world’ settings, are needed to clarify the risk of VTE in RA with other JAKi and the impact of (the type of) JAK inhibition as such on this risk.

In accordance with the 2019 SLR, the risk of serious infections was higher in patients on bDMARDs compared with patients on csDMARDs. Previous studies have demonstrated that the incidence of serious infections does not differ across bDMARDs and now new evidence extends this observation also to tofacitinib. The previous finding of a higher risk of TB with monoclonal TNFi than with etanercept and the lower risk with rituximab was not further studied. Data indicating that rituximab might increase the risk of severe infection by SARS-CoV-2 is aligned with a previous SLR informing the EULAR recommendation for the management of RMDs in the context to COVID-19.^{12–13}

The increased risk of infection by HZ with JAKi was again demonstrated. Patients on upadacitinib, baricitinib and tofacitinib (analysed together) were three times more likely to

be infected with HZ than patients on csDMARDs.³¹ In addition, infections were more common with tofacitinib than with bDMARDs in observational studies. RCTs included in this SLR, suggest an increased risk with upadacitinib, but not with filgotinib, compared with an active comparator. This finding is in line with pooled analyses of RCTs which report a similar incidence of infection by HZ with tofacitinib,¹¹⁷ baricitinib,¹¹⁸ and upadacitinib,¹¹⁹ (3.0–5.3/100 PY), but a lower incidence with filgotinib (1.1–1.8/100 PY).¹²⁰ This is, however, an indirect comparison of selected patients included in RCTs. Observational studies comparing JAKi are needed to evaluate if the risks differ across JAKi.

New data have shown again the increased risk of lower intestinal perforations with tocilizumab. The underlying mechanism remains unclear. In one study, both the risk of diverticulitis and diverticular perforation was increased with tocilizumab, but not the risk of other perforations.²⁶ This suggests that suppressing IL-6 predisposes to diverticulitis that, because of atypical clinical presentation (eg, low levels of C reactive protein), is more difficult to detect and perhaps more susceptible to perforation because of diagnostic delay. Even though IL-6 pathway inhibition is one of the effects of JAKi, in ORAL-Surveillance, the risk of perforation did not differ between tofacitinib and TNFi. It should be noted, however, that ORAL-Surveillance was likely underpowered to detect this difference. No observational studies on other IL-6Ri or JAKi could be included to clarify whether this is a class effect common to all drugs targeting IL-6.

Studies included in this SLR have shed new light on the safety aspects of drugs used in RA. Important questions that remain unanswered are expected to be addressed in the future as more studies, especially those on JAKi other than tofacitinib and IL-6Ri other than tocilizumab become available. This new evidence will inform future updates of the recommendations for the management of RA.

Author affiliations

¹CHRC Campus Nova Medical School, Lisboa, Portugal

²Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

³Division of Rheumatology, Department of Medicine, Medical University of Vienna, Wien, Austria

⁴2nd Department of Medicine, Hietzing Hospital, Wien, Austria

⁵Department of Clinical Sciences and Community Health, ASS G. Pini, University of Milan, Milano, Italy

⁶Department of Rheumatology, ASST PINI-CTO, Milan, Italy

⁷NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, UK

⁸Rheumatology, KU Leuven University Hospitals, Leuven, Belgium

⁹Engineering Research Centre, Leuven, Belgium

¹⁰Patient Research Partner Network, European Alliance of Associations for Rheumatology, Zurich, Switzerland

¹¹Medicine, Division of Rheumatology, University of Western Ontario Schulich School of Medicine & Dentistry, London, Ontario, Canada

¹²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine Graduate School of Medicine, Shinjuku-ku, Japan

¹³Saitama Medical University, Iruma-gun, Japan

¹⁴Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK

¹⁵NIHR Manchester Biomedical Research Centre, Manchester, UK

¹⁶School of Public Health, Oregon Health & Science University, Portland, Oregon, USA

¹⁷Section for Outcomes Research, Centre for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Wien, Austria

¹⁸Institute for Arthritis and Rehabilitation, Ludwig Boltzmann, Vienna, Austria

¹⁹Walaes Library, Leiden University Medical Center, Leiden, The Netherlands

²⁰Amsterdam Rheumatology Center, Amsterdam University Medical Centres, Amsterdam, The Netherlands

²¹Rheumatology, Zuyderland Medical Centre Heerlen, Heerlen, The Netherlands

Twitter Alexandre Sepriano @AlexSepriano and Janet Pope @Janetbirdope

Acknowledgements KLH is supported by the NIHR Manchester Biomedical Research Centre.

Collaborators N/A.

Contributors AS extracted the data for the SLR; JWS developed the search strategies; AS wrote the first version of the manuscript and all authors revised the manuscript critically for important intellectual content and gave final approval of the version to be published.

Funding European Alliance of Associations for Rheumatology.

Competing interests AS: received speaker/consulting fees from UCB, Novartis and Lilly AK: Speakers bureau, Consultancy: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Gilead, Janssen, Merck Sharp and Dohme, Novartis, UCB und Pfizer SAB: received an ASPIRE grant from Pfizer JS received grants from AbbVie, Astra-Zeneca, Janssen, Lilly, Novartis, Roche and honoraria from AbbVie, Amgen, Astra-Zeneca, Astra, BMS, Celgene, Celltrion, Chugai, Gilead, ILTOO, Janssen, Lilly, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, UCB DvdH: received consulting fees from AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma and is Director of Imaging Rheumatology by RC received consulting fees from AbbVie, BMS, Amgen, Celltrion, Eli-Lilly, Fresenius-Kabi, Galapagos, Janssen, MSD, Novartis, Pfizer, UCB Pharma. CJE Has received fees from AbbVie, Astra Zeneca, BMS, Celgene, Celltrion, Fresenius Kabi, Gilead, Galapagos, GSK, Janssen, Eli Lilly, Pfizer, Roche, Sanofi for advisory boards, speakers bureau and research support PV received consulting fees from AbbVie, BMS, Celltrion, Eli Lilly, Galapagos, Gilead, Nordic Pharma, Pfizer, Sidekick Health, UCB and speaker's fees from Eli Lilly, Galapagos, MSD and Roularta. Holds the Pfizer Chair Early RA Management at KU Leuven. SdS: none JEP received research grants from AbbVie, Fresenius Kabi, Mallinckrodt Pharmaceuticals, Pfizer, Seattle Genetics and consulting fees from AbbVie, Amgen, Astra Zeneca, BI, BMS, Celltrion, EMERALD, Fresenius Kabi, Galapagos, GSK, Janssen, Lilly, Mallinckrodt Pharmaceuticals, Medexus, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Roche, Sandoz, Samsung, Sobi, Viatrii TT received grants from AbbVie, Asahikasei, AYUMI, Chugai, Eli Lilly Japan, Mitsubishi-Tanabe, Ono, and honoraria from AbbVie, Asahikasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lilly Japan, Gilead Sciences, Janssen K.K., Mitsubishi-Tanabe, Pfizer Japan KLH: Honoraria from AbbVie (Speakers' fees) and Research Grants from Pfizer and BMS KIW received research grants from Pfizer, BMS, and GSK, and scientific consulting fees from UCB, AbbVie, BMS, Galapagos, Gilead, Lilly, GSK, Roche, and Novartis DA received grants, speaker fees, or consultancy fees from AbbVie, Amgen, Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, and Sobi TAS has received grant/research support from AbbVie and Roche, has been a consultant for AbbVie and Sanofi Genzyme, and has been a paid speaker for AbbVie, Novartis, Roche, Sanofi, and Takeda JWS: none RBML received consulting fees from AbbVie, BMS, Celgene, Eli-Lilly, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Roche, UCB and is Director of Rheumatology Consultancy by JSS, DvdH, KLH, KIW, DA and RBML are members of the Editorial Board of ARD.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs

Alexandre Sepriano <http://orcid.org/0000-0003-1954-0229>

Andreas Kerschbaumer <http://orcid.org/0000-0002-6685-8873>

Sytske Anne Bergstra <http://orcid.org/0000-0002-7136-5248>

Josef S Smolen <http://orcid.org/0000-0002-4302-8877>

Désirée van der Heijde <http://orcid.org/0000-0002-5781-158X>

Patrick Verschueren <http://orcid.org/0000-0002-0340-3580>

Savia de Souza <http://orcid.org/0000-0003-4953-3257>

Janet Pope <http://orcid.org/0000-0003-1479-5302>

Tsutomu Takeuchi <http://orcid.org/0000-0003-1111-8218>

Kimme Hyrich <http://orcid.org/0000-0001-8242-9262>

Kevin L Winthrop <http://orcid.org/0000-0002-3892-6947>

Daniel Aletaha <http://orcid.org/0000-0003-2108-0030>

Tanja Stamm <http://orcid.org/0000-0003-3073-7284>

Jan W Schoones <http://orcid.org/0000-0003-1120-4781>

Robert B M Landewé <http://orcid.org/0000-0002-0577-6620>

REFERENCES

- Smolen JS, Landewé RBM, Bijlsma JWJ, *et al.* EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis* 2020;79:685–99.
- Giles JT, Sattar N, Gabriel S, *et al.* Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. *Arthritis Rheumatol* 2020;72:31–40.
- Ytterberg SR, Bhatt DL, Mikuls TR, *et al.* Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. *N Engl J Med* 2022;386:316–26.
- Smolen JS, van der Heijde D, Machold KP, *et al.* Proposal for a new nomenclature of disease-modifying antirheumatic drugs. *Ann Rheum Dis* 2014;73:3–5.
- Kerschbaumer A, Sepriano A, Smolen JS, *et al.* Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. *Ann Rheum Dis* 2020;79:744–59.
- Sepriano A, Kerschbaumer A, Smolen JS, *et al.* Safety of synthetic and biological DMARDs: a systematic literature review Informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis* 2020;79:760–70.
- Landewé RBM. Methotrexate saves lives: a pearl of observational research. *Arthritis Rheum* 2013;65:307–9.
- Smolen J, Landewé R, *et al.* EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update, 2022.
- Kerschbaumer A, Sepriano A, Bergstra SA. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research Informing the 2022 update of the EULAR recommendations for management of rheumatoid arthritis, 2022.
- Bergstra SA, Sepriano A, Kerschbaumer A. Persistence, efficacy and safety of glucocorticoids: a systematic literature review Informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis, 2022.
- Sackett DWR, Rosenberg W, *et al.* Evidence-based medicine: how to practice and teach EBM. London: Churchill Livingstone, 1997.
- Kroon FPB, Najm A, Alunno A, *et al.* Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. *Ann Rheum Dis* 2022;81:422–32.
- Landewé RBM, Kroon FPB, Alunno A, *et al.* EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. *Ann Rheum Dis* 2022;81:1628–9.
- Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. *Ann Intern Med* 2006;144:427–37.
- Higgins JPT, Altman DG, Gotzsche PC, *et al.* The cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- Koh JH, Lee S-K, Kim J, *et al.* Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO registry. *Clin Exp Rheumatol* 2021;39:269–78.
- Chen H-K, Shao S-C, Weng M-Y, *et al.* Risk of heart failure in rheumatoid arthritis patients treated with tumor necrosis factor- α inhibitors. *Clin Pharmacol Ther* 2021;110:1595–603.
- Xie F, Yun H, Levitan EB, *et al.* Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients. *Arthritis Care Res* 2019;71:1004–18.
- Xie F, Chen L, Yun H, *et al.* Benefits of methotrexate use on cardiovascular disease risk among rheumatoid arthritis patients initiating biologic disease-modifying antirheumatic drugs. *J Rheumatol* 2021;48:804–12.
- Ozen G, Pedro S, Michaud K. The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis. *J Rheumatol* 2021;48:648–55.
- Liang H, Danwada R, Guo D, *et al.* Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. *RMD Open* 2019;5:e001013.
- He M, Pawar A, Desai RJ, *et al.* Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: a propensity score-matched cohort study. *Semin Arthritis Rheum* 2021;51:1242–50.
- Chen C-P, Kung P-T, Chou W-Y, *et al.* Effect of introducing biologics to patients with rheumatoid arthritis on the risk of venous thromboembolism: a nationwide cohort study. *Sci Rep* 2021;11:17009.
- Desai RJ, Pawar A, Khosrow-Khavar F, *et al.* Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. *Rheumatology* 2021;61:121–30.
- Barbulescu A, Delcoigne B, Askling J, *et al.* Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study. *RMD Open* 2020;6:e001201.
- Rempenault C, Lukas C, Combe B, *et al.* Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. *Rheumatology* 2022;61:953–62.
- Curtis JR, Zhou X, Rubin DT, *et al.* Characteristics, comorbidities, and outcomes of SARS-CoV-2 infection in patients with autoimmune conditions treated with systemic therapies: a population-based study. *J Rheumatol* 2022;49:320–9.
- Raiker R, DeYoung C, Pakhchanian H, *et al.* Outcomes of COVID-19 in patients with rheumatoid arthritis: a multicenter research network study in the United States. *Semin Arthritis Rheum* 2021;51:1057–66.
- Chen M-H, Lee I-C, Chen M-H, *et al.* Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. *Ann Rheum Dis* 2021;80:1393–9.
- Curtis JR, Xie F, Yang S, *et al.* Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids. *Arthritis Care Res* 2019;71:1249–54.
- Redeker I, Albrecht K, Kekow J, *et al.* Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German rabbit register. *Ann Rheum Dis* 2022;81:41–7.
- Bechman K, Halai K, Yates M, *et al.* Nonserious infections in patients with rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis. *Arthritis Rheumatol* 2021;73:1800–9.
- Leon L, Peñuelas M, Candel FJ, *et al.* Indicator opportunistic infections after biological treatment in rheumatoid arthritis, 10 years follow-up in a real-world setting. *Ther Adv Musculoskelet Dis* 2019;11:1759720X1987800.
- Ohmura S-I, Homma Y, Masui T, *et al.* Factors associated with pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving methotrexate: a single-center retrospective study. *Intern Med* 2022;61:11.
- Ozen G, Pedro S, England BR, *et al.* Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease-modifying antirheumatic drugs. *ACR Open Rheumatol* 2019;1:424–32.
- Ranza R, de la Vega MC, Laurindo IMM, *et al.* Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries biobadabril and biobadasar. *Clin Rheumatol* 2019;38:2129–39.
- Montastruc F, Renoux C, Hudson M, *et al.* Abatacept initiation in rheumatoid arthritis and the risk of serious infection: a population-based cohort study. *Semin Arthritis Rheum* 2019;48:1053–8.
- Kremer JM, Reed G, Pappas DA, *et al.* Hydroxychloroquine and the risk of respiratory infections among RA patients. *RMD Open* 2020;6:e001389.
- Grøn KL, Glinthorg B, Nørgaard M, *et al.* Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study. *Rheumatology* 2020;59:1949–56.
- Chen SK, Liao KP, Liu J, *et al.* Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study. *Arthritis Care Res* 2020;72:9–17.
- Jeon H-L, Kim SC, Park S-H, *et al.* The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea. *Semin Arthritis Rheum* 2021;51:989–95.
- Chen H-H, Lin C-H, Wang C-Y, *et al.* Association of hospitalised infection with socioeconomic status in patients with rheumatoid arthritis receiving biologics or tofacitinib: a population-based cohort study. *Front Med* 2021;8.
- Patel V, Pulungan Z, Shah A, *et al.* Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs. *J Med Econ* 2021;24:299–307.
- Krabbe S, Grøn KL, Glinthorg B, *et al.* Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model. *Rheumatology* 2021;60:3834–44.
- Pawar A, Desai RJ, Gautam N, *et al.* Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. *Lancet Rheumatol* 2020;2:e84–98.
- Kang EH, Jin Y, Tong AY, *et al.* Risk of serious infection among initiators of tumor necrosis factor inhibitors plus methotrexate versus triple therapy for rheumatoid arthritis: a cohort study. *Arthritis Care Res* 2020;72:1383–91.
- Rotar Z, Svetina P, Tomsic M, *et al.* Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study. *BMJ Open* 2020;10:e034356.
- de Gernay S, Bagheri H, Despas F, *et al.* Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. *Rheumatology* 2020;59:2360–7.
- Kim SC, Pawar A, Desai RJ, *et al.* Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study. *Semin Arthritis Rheum* 2019;49:222–8.
- Staples MP, March L, Hill C, *et al.* Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian rheumatology association database (ARAD) prospective cohort study. *BMC Rheumatol* 2019;3:1.

- 51 Jung SM, Kwok S-K, Ju JH, *et al.* Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean national health insurance claims data. *Korean J Intern Med* 2019;34:669–77.
- 52 Montastruc F, Renoux C, Dell'Aniello S, *et al.* Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. *Rheumatology* 2019;58:683–91.
- 53 Hellgren K, Di Giuseppe D, Smedby KE, *et al.* Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs—a Swedish cohort study of risks by time, drug and lymphoma subtype. *Rheumatology* 2021;60:809–19.
- 54 Ebina K, Hashimoto M, Yamamoto W, *et al.* Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the answer cohort study. *Arthritis Res Ther* 2019;21:91.
- 55 Ebina K, Hirano T, Maeda Y, *et al.* Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the answer cohort study. *Arthritis Res Ther* 2020;22:142.
- 56 Jinno S, Onishi A, Dubreuil M, *et al.* Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis—the answer cohort study. *Arthritis Res Ther* 2021;23:116.
- 57 Ebina K, Hirano T, Maeda Y, *et al.* Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the answer cohort study. *Clin Rheumatol* 2021;40:2673–80.
- 58 Akhlaghi S, Sahebali M, Mahmoodi M, *et al.* Casual effect of methotrexate+etanercept/infliximab on survival of patients with rheumatoid arthritis. *Pragmat Obs Res* 2019;10:23–8.
- 59 Lee EE, Shin A, Lee J, *et al.* All-cause and cause-specific mortality of patients with rheumatoid arthritis in Korea: a nation-wide population-based study. *Joint Bone Spine* 2022;89:105269.
- 60 Kopp TI, Delcoigne B, Arkema EV, *et al.* Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. *Ann Rheum Dis* 2020;79:566–72.
- 61 Taylor TRP, Galloway J, Davies R, *et al.* Demyelinating events following initiation of Anti-TNF α therapy in the British Society for rheumatology biologics registry in rheumatoid arthritis. *Neurol Neuroimmunol Neuroinflamm* 2021;8. doi:10.1212/NXI.0000000000000992. [Epub ahead of print: 16 04 2021].
- 62 Hellgren K, Secher AE, Glinborg B. Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis. *Rheumatology* 2021.
- 63 Lau AN, Thorne JC, Movahedi M, *et al.* Effect of concomitant disease-modifying antirheumatic drugs and methotrexate administration route on biologic treatment durability in rheumatoid arthritis: OBRI cohort results. *J Rheumatol* 2019;46:874–86.
- 64 Gottenberg J-E, Morel J, Perrodeau E, *et al.* Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study. *BMJ* 2019;364:l67.
- 65 Movahedi M, Hepworth E, Mirza R, *et al.* Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: results from a real-world rheumatoid arthritis cohort. *Semin Arthritis Rheum* 2020;50:915–22.
- 66 Finckh A, Tellenbach C, Herzog L, *et al.* Comparative effectiveness of antitumor necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. *RMD Open* 2020;6:e001174.
- 67 Bredemeier M, Ranza R, Kakehasi AM, *et al.* Safety of the methotrexate-leflunomide combination in rheumatoid arthritis: results of a multicentric, registry-based, cohort study (BiodadaBrasil). *J Rheumatol* 2022;49:122.
- 68 Faselis C, Zeng-Treitler Q, Cheng Y, *et al.* Cardiovascular safety of hydroxychloroquine in US veterans with rheumatoid arthritis. *Arthritis Rheumatol* 2021;73:1589–600.
- 69 Khosrow-Khavar F, Kim SC, Lee H, *et al.* Tofacitinib and risk of cardiovascular outcomes: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study. *Ann Rheum Dis* 2022;81:798–804.
- 70 Hsieh M-J, Lee C-H, Tsai M-L, *et al.* Biologic agents reduce cardiovascular events in rheumatoid arthritis not responsive to tumour necrosis factor inhibitors: a national cohort study. *Can J Cardiol* 2020;36:1739–46.
- 71 Kremer JM, Bingham CO, Cappelli LC, *et al.* Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. *ACR Open Rheumatol* 2021;3:173–84.
- 72 Bower H, Frisell T, di Giuseppe D, *et al.* Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. *RMD Open* 2021;7:e001987.
- 73 Ozen G, Pedro S, Schumacher R, *et al.* Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study. *Arthritis Res Ther* 2019;21:141.
- 74 Simon TA, Boers M, Hochberg M, *et al.* Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. *Arthritis Res Ther* 2019;21:228.
- 75 Aletaha D, Bingham CO, Karpouzas GA, *et al.* Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). *RMD Open* 2021;7:e001465.
- 76 Burmester GR, Strand V, Rubbert-Roth A, *et al.* Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. *RMD Open* 2019;5:e001017.
- 77 Combe B, Kivitz A, Tanaka Y, *et al.* Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. *Ann Rheum Dis* 2021;80:848–58.
- 78 Emery P, van Hoogstraten H, Thangavelu K, *et al.* Subcutaneous sarilumab in patients with rheumatoid arthritis who previously received subcutaneous sarilumab or intravenous tocilizumab: an open-label extension of a randomized clinical trial. *ACR Open Rheumatol* 2020;2:672–80.
- 79 Fleischmann R, Genovese MC, Maslova K, *et al.* Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors. *Rheumatology* 2021;60:4991–5001.
- 80 Fleischmann R, Pangan AL, Song I-H, *et al.* Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. *Arthritis Rheumatol* 2019;71:1788–800.
- 81 Fleischmann R, Takeuchi T, Schiff M, *et al.* Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate. *Arthritis Care Res* 2020;72:1112–21.
- 82 Fleischmann RM, Blanco R, Hall S, *et al.* Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. *Ann Rheum Dis* 2021;80:432–9.
- 83 Fleischmann RM, Genovese MC, Enejosa JV, *et al.* Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. *Ann Rheum Dis* 2019;78:1454–62.
- 84 Genovese MC, Durez P, Fleischmann R, *et al.* Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies. *Eur J Rheumatol* 2021;8:120–9.
- 85 Genovese MC, Greenwald MW, Gutierrez-Ureña SR, *et al.* Two-year safety and effectiveness of Peficitinib in moderate-to-severe rheumatoid arthritis: a phase IIb, open-label extension study. *Rheumatol Ther* 2019;6:503–20.
- 86 Genovese MC, Kalunian K, Gottenberg J-E, *et al.* Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the finch 2 randomized clinical trial. *JAMA* 2019;322:315–25.
- 87 Genovese MC, van der Heijde D, Lin Y, *et al.* Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. *RMD Open* 2019;5:e000887.
- 88 Kameda H, Takeuchi T, Yamaoka K, *et al.* Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). *Arthritis Res Ther* 2021;23:9.
- 89 Kameda H, Takeuchi T, Yamaoka K, *et al.* Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. *Rheumatology* 2020;59:3303–13.
- 90 Kameda H, Wada K, Takahashi Y, *et al.* Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: a Japan phase 3 trial (HARUKA). *Mod Rheumatol* 2020;30:239–48.
- 91 Kavanaugh A, Westhovens RR, Winthrop KL, *et al.* Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase II rheumatoid arthritis programs. *J Rheumatol* 2021;48:1230–8.
- 92 Nasonov E, Fatenejad S, Feist E, *et al.* Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. *Ann Rheum Dis* 2022;81:469–79.
- 93 Rubbert-Roth A, Enejosa J, Pangan AL, *et al.* Trial of upadacitinib or abatacept in rheumatoid arthritis. *N Engl J Med* 2020;383:1511–21.
- 94 Smolen JS, Pangan AL, Emery P, *et al.* Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (select-monotherapy): a randomised, placebo-controlled, double-blind phase 3 study. *Lancet* 2019;393:2303–11.
- 95 Takeuchi T, Genovese MC, Haraoui B, *et al.* Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study. *Ann Rheum Dis* 2019;78:171–8.
- 96 Takeuchi T, Tanaka Y, Soen S, *et al.* Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (desirable study): a randomised, double-blind, placebo-controlled phase 3 trial. *Ann Rheum Dis* 2019;78:899–907.
- 97 Takeuchi T, Tanaka Y, Tanaka S, *et al.* Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: final results (32 months of mean

- peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. *Rheumatol Ther* 2021;8:425–42.
- 98 Takeuchi T, Tanaka Y, Tanaka S, *et al.* Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan. *Arthritis Res Ther* 2020;22:47.
 - 99 Tanaka Y, Fautrel B, Keystone EC, *et al.* Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. *Ann Rheum Dis* 2019;78:890–8.
 - 100 Tanaka Y, Takeuchi T, Soen S, *et al.* Effects of denosumab in Japanese patients with rheumatoid arthritis treated with conventional antirheumatic drugs: 36-month extension of a phase III study. *J Rheumatol* 2021;48:1663–71.
 - 101 van Vollenhoven R, Takeuchi T, Pangan AL, *et al.* Efficacy and safety of upadacitinib monotherapy in methotrexate-naïve patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. *Arthritis Rheumatol* 2020;72:1607–20.
 - 102 Westhovens R, Rigby WFC, van der Heijde D, *et al.* Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled finch 3 trial. *Ann Rheum Dis* 2021;80:727–38.
 - 103 ANNEX I summary of product characteristics. Available: https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf [Accessed 10 May 2022].
 - 104 ANNEX I summary of product characteristics. Available: https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf [Accessed 10 May 2022].
 - 105 ANNEX I summary of product characteristics. Available: https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_en.pdf [Accessed 10 May 2022].
 - 106 ANNEX I summary of product characteristics. Available: https://www.ema.europa.eu/en/documents/product-information/jyseleca-epar-product-information_en.pdf [Accessed 10 May 2022].
 - 107 Janus Kinase inhibitors (JAKi). Available: <https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki> [Accessed 04 May 2022].
 - 108 Highlights of prescribing information these highlights do not include all the information needed to use OLUMIANT safely and effectively. see full prescribing information for OLUMIANT. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207924s004lbl.pdf [Accessed 10 May 2022].
 - 109 Highlights of prescribing information these highlights do not include all the information needed to use RINVOQ safely and effectively. see full prescribing information for RINVOQ. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211675s004lbl.pdf [Accessed 10 May 2022].
 - 110 Highlights of prescribing information these highlights do not include all the information needed to use XELJANZ/XELJANZ XR/XELJANZ oral solution safely and effectively. see full prescribing information for XELJANZ/XELJANZ XR/XELJANZ oral solution. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203214s028,208246s013,213082s003lbl.pdf [Accessed 10 May 2022].
 - 111 Avina-Zubieta JA, Thomas J, Sadatsafavi M, *et al.* Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. *Ann Rheum Dis* 2012;71:1524–9.
 - 112 Ogdie A, Yu Y, Haynes K, *et al.* Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. *Ann Rheum Dis* 2015;74:326–32.
 - 113 Simon TA, Thompson A, Gandhi KK, *et al.* Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. *Arthritis Res Ther* 2015;17:212.
 - 114 Barnabe C, Martin B-J, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. *Arthritis Care Res* 2011;63:522–9.
 - 115 Roubille C, Richer V, Starnino T, *et al.* The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. *Ann Rheum Dis* 2015;74:480–9.
 - 116 Mercer LK, Galloway JB, Lunt M, *et al.* Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British society for rheumatology biologics register for rheumatoid arthritis. *Ann Rheum Dis* 2017;76:497–503.
 - 117 Winthrop KL, Yamanaka H, Valdez H, *et al.* Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. *Arthritis Rheumatol* 2014;66:2675–84.
 - 118 Taylor PC, Takeuchi T, Burmester GR, *et al.* Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. *Ann Rheum Dis* 2022;81:335–43.
 - 119 Winthrop KL, Nash P, Yamaoka K, *et al.* Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. *Ann Rheum Dis* 2022;81:206–13.
 - 120 Winthrop KL, Tanaka Y, Takeuchi T, *et al.* Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. *Ann Rheum Dis* 2022;81:184–92.